Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamapimod + pioglitazone for hospitalized COVID-19
2020-005849-16Phase 2Terminated
- Sponsor
- Curatis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Pamapimod + pioglitazone with Placebo control (2 arms). Primary endpoint: Percentage of participants alive and free of oxygen therapy. Started Dec 2020; status: terminated.
02
Drugs
pamapimodpioglitazone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005849-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005849-16.